http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2533288-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b237654743cfc467cfb349019c9b4240 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b3d33ed0e9ad042d6bc0458ee62cef23 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-554 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-138 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-201 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 |
| filingDate | 2012-09-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2014-11-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e05eec0c9a94a3e5cfef370d690a044b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bc19e8139d12422eda89b22590e6d594 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0a7cf983e21e5cf01f016f192a3d03ad http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8cf21319590e4b9faa1f959e517077c5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0a1bccf203c0e689f84078b41a105dd5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_94b727ec042183e615e398ce1a1130e1 |
| publicationDate | 2014-11-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2533288-C2 |
| titleOfInvention | Potassium channel inhibitors as therapeutic agents in lymphoma and leukaemia |
| abstract | FIELD: medicine, pharmaceutics. n SUBSTANCE: invention refers to molecular biology, molecular genetics and biotechnology, and can be used in medicine, as well as in agriculture and industrial biotechnology for the development of a fundamentally new approach to antileukaemic therapy with the use of low-molecular compounds against specific molecular targets, which include molecules of subunits of voltage-gated potassium channels of the family Kv. What is presented is using potassium channel inhibitors specified in diltiazem hydrochloride, anandamide (arachidonylethanolamide), verapamil hydrochloride, linoleic acid as an agent for enhancing the apoptosis of tumour B-cells in chronic lymphatic leukaemia. The technical effect is achieved by the fact that the low-molecular compounds are used to simulate the inhibitory effect of the KCNRG protein, which inhibits the normal assembly of potassium channel proteins by binding to the region responsible for their tetramerisation and thereby suppressing the channel activity. n EFFECT: creating the potassium channel inhibitors used as an agent to induce the apoptosis of tumour B-cells in chronic lymphatic leukaemia. n 2 dwg, 3 tbl |
| priorityDate | 2012-09-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 96.